Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

Sociedad de Lucha Contra el Cáncer del Ecuador

Status: Not yet enrolling

Conditions: Lymphoma, B-Cell; Metabolomics; Neoplasms; High-grade B-cell Lymphoma; Cancer; Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma

Treatments: Diagnostic Test: Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)

Study type: Observational

Funder types: Other

Identifiers

NCT05834426

CISOLGYE20230021

Details and patient eligibility

About

The goal of this observational study is to determine the plasma metabolomic profile in diffuse large B-cell lymphoma and high-grade B lymphomas patients before, during and after treatment by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)

Full description

The main question it aims to answer is the correlation between the plasma metabolomic profile of diffuse large B-cell lymphoma and high-grade B lymphomas patients before and after treatment determined by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) and analysed with MetaboAnalyst web platform to identify specific over- or under-expressed markers.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years and older;
• Both sexes;
• Patients with confirmed histopathological diagnosis of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma;
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;
• Patient intending to receive full-dose treatment (Monoclonal antibodies plus anthracycline based combination chemotherapy);
• Staged with PET-CT or CT.

Exclusion criteria

• Patients with comorbidities that may interfere with the interpretation of the results (CKD in dialysis phase, Autoimmune diseases, uncontrolled Diabetes Mellitus (DM), symptomatic Heart Failure (CHF), HIV positive, positive serology for hepatitis B and C);
• Patients requiring multiple blood transfusions (4 or more blood components for the same period or cause);
• Pregnant women;
• First-line treatment in another institution;
• Diffuse transformed Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma